Biodistribution and pharmacokinetics of 111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model: Implications for novel targeting strategies

British Journal of Cancer

Volumn 83, Issue 2, 2000, Pages 232-238

  Harrington, K J ^a,b   Rowlinson Busza, G ^a   Syrigos, K N ^a   Uster, P S ^c   Abra, R M ^c   Stewart, J S W ^d  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b MAYO CLINIC   (United States)

^c ALZA CORPORATION   (United States)

^d CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

Biodistribution; Head and neck cancer; Pegylated liposomes; Pharmacokinetics; Tumour targeting; Xenograft tumour

Indexed keywords

LIPOSOME; PENTETATE INDIUM IN 111; CHELATING AGENT; DRUG CARRIER; INDIUM; PENTETIC ACID;

ADRENAL GLAND; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG TARGETING; DRUG UPTAKE; FEMALE; FEMALE GENITAL SYSTEM; HUMAN; HUMAN CELL; KIDNEY; LIVER; MOUSE; MUSCULOSKELETAL SYSTEM; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; SKIN; SPLEEN; XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; DRUG STABILITY; HEAD AND NECK TUMOR; METABOLISM; TIME; TISSUE DISTRIBUTION;

ANIMALS; CHELATING AGENTS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; LIPOSOMES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PENTETIC ACID; TIME FACTORS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0033624061     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1232     Document Type: Article

References (37)

1. Allen TM and Chonn A (1987) Large unilamellar liposomes with low uptake by the reticuloendothelial system. FEBS Lett 223: 42-46
2. Bangham AD, Standish HM and Watkins JC (1965) Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol 13: 238-252
3. Berry G, Billingham M, Alderman E, Torti F, Lum B, Dumond C and Martin F (1996) Reduced cardiotoxicity of DOXIL (pegylated liposomal doxorubicin) in AIDS Kaposi's sarcoma patients compared to a matched control group of cancer patients given doxorubicin. Proceedings of the American Society of Clinical Oncologists 15: 303 (abstract 843)
4. Britten RA, Evans AJ, Allalunis-Turner MJ (1996) Effect of cisplatin on the clinically-relevant radiosensitivity of human cervical carcinoma cell lines. Int J Radiat Oncol Biol Phys 34: 367-374
5. Eagle H. Propagation in a fluid medium of a human epidermoid carcinoma. Strain KB (1955) Proc Soc Exp Biol Med 89: 362-364
6. Gabizon AA (1994) Liposomal anthracyclines. Hematol Oncol Clin N America 8: 431-450
7. Gabizon A, Papahadjopoulos D (1988) Liposome formulations with prolonged circulation time in blood and enhanced uptake in tumours. Proc Natl Acad Sci USA 85: 6949-6953
8. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y (1994) Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polethylene-glycol coated liposomes. Cancer Res 54: 987-992
9. Goebel F-D, Goldstein D, Goos M, Jablonowski H, Stewart JS (1996) Efficacy and safety of Stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Br J Cancer 73: 989-994
10. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, Von Roenn J (1995) Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy. Cancer 75: 2169-2173
11. Gregoriades G, Swain CP, Wills EJ, Tavill AS (1974) Drug-carrier potential of liposomes in cancer chemotherapy. Lancet 1: 1313-1316
12. Harrison M, Tomlinson D, Stewart S (1995) Liposomal entrapped doxorubicin: an active agent in AIDS-related Kaposi's sarcoma. J Clin Oncol 13: 914-920
13. Huang SK, Lee K-D, Hong K, Friend DS, Papahadjopoulos D (1992) Microscopic localisation of sterically stabilised liposomes in colon carcinoma-bearing mice. Cancer Res 52: 5135-5143
14. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D, Friend DS (1993) Extravasation and transcytosis of liposomes in Kaposi's sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am J Pathol 143: 1-14
15. Lasic DD, Papahadjopoulos D (1995) Liposomes revisited. Science 267: 1275-1276
16. Madhavan S, Northfelt DW (1995) Lack of vesicant injury following extravasation of liposomal doxorubicin. J Natl Cancer Inst 87: 1556-1557
17. Maraveyas A, Stafford N, Rowlinson-Busza G, Stewart JSW, Epenetos AA (1995) Pharmacokinetics, biodistribution and dosimetry of specific and control radiolabelled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Cancer Res 55: 1060-1069
18. Martin FJ (1997) Future prospects for Stealth liposomes in cancer therapy. Oncology 11 (suppl 11): 63-68
19. Mayhew EG, Lasic D, Babbar S, Martin FJ (1992) Pharmacokinetics and antitumour activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycol-derivatized phospholipid. Int J Cancer 51: 302-309
20. McGinn CJ, Kinsella TJ (1992) The experimental and clinical rationale for the use of S-Phase-specific radiosensitisers to overcome tumour cell repopulation. Semin Oncol 4: 21-28
21. Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uzìely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso L, Liang L-J (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumour activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15: 987-993
22. Newman MS, Colbern GT, Working PK, Engbers C, Amantea MA (1999) Comparative pharmacokinetics, tissue distribution and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumour-bearing mice. Cancer Chemother Pharmacol 43: 1-7
23. Ng TT, Denning DW (1995) Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom Compassionate use data. Arch Intern Med 155: 1093-1098
24. Northfelt DW, Dezube B, Thommes JA, Miller BJ, Fischl MA, Friedman-Kien A, Kaplan LD, DuMond C, Mamelok RD, Henry DH (1998) Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomised phase III clinical trial. J Clin Oncol 16: 2445-2451
25. Papahadjopoulos D, Allen TM, Gabizon A, Mayhew E, Matthay K, Huang SK, Lee K-D, Woodle MC, Lasic DD, Redemann C, Martin FJ (1991) Sterically stabilised liposomes: Improvements in pharmacokinetics and anti-tumour therapeutic efficacy. Proc Natl Acatl Sci USA 88: 11460-11464
26. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A (1997) Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicentre phase II trial. J Clin Oncol 15: 3185-3191
27. Russo R, Nigro LC, Minniti S (1996) Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 32: 133-137
28. Saunders M, Dische S (1996) Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide. Br J Cancer 74: S271-S278
29. Siegal T, Horowitz A, Gabizon A (1995) Doxorubicin encapsulated in sterically stabilised liposomes for the treatment of a brain tumour model: biodistribution and therapeutic efficacy. J Neurosurg 83: 1029-1037
30. Stewart JSW, Jablonowski H, Goebel F-D, Arasteh K, Spittle M, Rios A, Aboulafia D, Galleshaw J, Dezube BJ (1998) Randomised comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. J Clin Oncol 16: 683-691
31. Vaage J, Barbera-Guillem E, Abra R, Huang A, Working P (1994) Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts. Cancer 73: 1478-1484
32. Vaage J, Donovan D, Loftus T, Working P (1995) Prevention of metastasis from mouse mammary carcinomas with liposomes carrying doxorubicin. Br J Cancer 72: 1074-1075
33. Vaage J, Donovan D, Mayhew E, Uster P, Woodle M (1993a) Therapy of mouse mammary carcinomas with vincristine and doxorubicin encapsulated in sterically stabilised liposomes. Int J Cancer 54: 959-964
34. Vaage J, Mayhew E, Lasic D, Martin F (1992) Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes. Int J Cancer 51: 942-948
35. Vaage J, Donovan D, Mayhew E, Abra R, Huang A (1993b) Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilised liposomes. Cancer 72: 3671-3675
36. Vaage J, Donovan D, Wipff E, Abra R, Colbern G, Uster P, Working P (1999) Therapy of a xenografted human colonic carcinoma using cisplatin or doxorubicin encapsulated in long-circulating pegylated stealth liposomes. Int J Cancer 80: 134-137
37. Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ, Bankert RB (1993) Arrest of human lung tumour xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilised liposomes. Cancer Res 53: 3964-3967